In Vitro Pharmacodynamic Effects of Cangrelor on Platelet P2Y 12 Receptor–Mediated Signaling in Ticagrelor-Treated Patients

JACC: Cardiovascular Interventions

Volumn 10, Issue 13, 2017, Pages 1374-1375

  Rollini, Fabiana ^a   Franchi, Francesco ^a   Thano, Estela ^a   Faz, Gabriel ^a   Park, Yongwhi ^a   Kureti, Megha ^a   Cho, Jung Rae ^a   Been, Latonya ^a   Bass, Theodore A ^a   Angiolillo, Dominick J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CANGRELOR; PURINERGIC P2Y12 RECEPTOR; TICAGRELOR; VASODILATOR STIMULATED PHOSPHOPROTEIN; ACTIN BINDING PROTEIN; ADENOSINE PHOSPHATE; ANTITHROMBOCYTIC AGENT; BIOLOGICAL MARKER; CELL ADHESION MOLECULE; P2RY12 PROTEIN, HUMAN; PHOSPHOPROTEIN; PURINERGIC P2Y RECEPTOR ANTAGONIST; VASODILATOR-STIMULATED PHOSPHOPROTEIN;

DRUG BLOOD LEVEL; HUMAN; LETTER; PHARMACODYNAMICS; PLATELET REACTIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIGNAL TRANSDUCTION; THROMBOCYTE AGGREGATION; ANALOGS AND DERIVATIVES; BLOOD; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; METABOLISM; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE; TIME FACTOR;

ADENOSINE MONOPHOSPHATE; BIOMARKERS; BLOOD PLATELETS; CELL ADHESION MOLECULES; DRUG SYNERGISM; HUMANS; MICROFILAMENT PROTEINS; PHOSPHOPROTEINS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P2Y12; SIGNAL TRANSDUCTION; TICAGRELOR; TIME FACTORS;

EID: 85021810281     PISSN: 19368798     EISSN: 18767605     Source Type: Journal    
DOI: 10.1016/j.jcin.2017.04.027     Document Type: Letter

References (5)

1. Franchi, F., Rollini, F., Angiolillo, D.J., Antithrombotic therapy for patients with STEMI undergoing primary PCI. Nat Rev Cardiol 14 (2017), 361–379.
2. Tello-Montoliu, A., Tomasello, S.D., Ferreiro, J.L., et al. Pharmacodynamic effects of prasugrel dosing regimens in patients on maintenance prasugrel therapy: results of a prospective randomized study. J Am Coll Cardiol 59 (2012), 1681–1687.
3. Cho, J.R., Rollini, F., Franchi, F., et al. Pharmacodynamic effects of ticagrelor dosing regimens in patients on maintenance ticagrelor therapy: results from a prospective, randomized, double-blind investigation. J Am Coll Cardiol Intv 8 (2015), 1075–1083.
4. Rollini, F., Franchi, F., Angiolillo, D.J., Switching P2Y12-receptor inhibitors in patients with coronary artery disease. Nat Rev Cardiol 13 (2016), 11–27.
5. Rollini, F., Franchi, F., Tello-Montoliu, A., et al. Pharmacodynamic effects of cangrelor on platelet P2Y12 receptor-mediated signaling in prasugrel-treated patients. J Am Coll Cardiol Intv 7 (2014), 426–434.